Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Halozyme Q1 Loss Widens - Quick Facts

Halozyme Therapeutics, Inc. (HALO: Quote) Monday reported a first-quarter loss of $15.1 million or $0.14 per share, which widened from $9.6 million or $0.10 per share in the year-ago period.

On average, eight analysts polled by Thomson Reuters expected the company to report a loss of $0.11 per share for the first quarter. Analysts' estimates typically exclude special items.

First-quarter revenues declined to $7.4 million from $7.5 million last year. Analysts expected revenues of $7.31 million for the quarter.

Click here to receive FREE breaking news email alerts for Halozyme Therapeutics, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After seeing initial strength on the heels of upbeat economic data, stocks have fluctuated over the course of early trading on Wednesday. The major averages have pulled back off their highs for the young session, with the Dow sliding into negative territory. After reporting a notable contraction in U.S. economic activity in the first quarter, the Commerce Department released a report on Wednesday showing that gross domestic product rebounded by more than anticipated in the second quarter. Employment in the U.S. private sector continued to see notable growth in the month of July, according to a report released by payroll processor ADP on Wednesday, although the pace of job growth came in below economist estimates.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.